ANBL1821: A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed Refractory or Progressive Neuroblastoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Neuroblastoma
-
Age: Between 1 years - 18 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Patients must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines, (i.e. > 2 x upper limit of normal [ULN]), at the time of initial diagnosis. 2) Patients must have at least ONE of the following at the time of enrollment: Measurable tumor on magnetic resonance imaging (MRI) or computed tomography (CT) scan.
You may not be eligible for this study if the following are true:
-
1) Pregnant women. 2) Patients who have received drugs that are strong inducers or inhibitors of CYP3A4 within 7 days prior to study enrollment. 3) Patients with symptoms of congestive heart failure.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
